Page last updated: 2024-09-03

imatinib mesylate and Non-alcoholic Fatty Liver Disease

imatinib mesylate has been researched along with Non-alcoholic Fatty Liver Disease in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
AlAsfoor, S; Bosch, AJT; Calabrese, D; Cavelti-Weder, C; Dervos, T; Matter, MS; Rohm, TV; Weber, A1
Kim, DH; Kim, J; Kwon, JS; Lee, JW; Lee, S; Lee, SK; Sandhu, J; Tontonoz, P1

Other Studies

2 other study(ies) available for imatinib mesylate and Non-alcoholic Fatty Liver Disease

ArticleYear
Imatinib reduces non-alcoholic fatty liver disease in obese mice by targeting inflammatory and lipogenic pathways in macrophages and liver.
    Scientific reports, 2018, 10-17, Volume: 8, Issue:1

    Topics: Adipose Tissue; Animals; Gene Expression Regulation; Humans; Imatinib Mesylate; Inflammation; Lipogenesis; Liver; Macrophages; Male; Mice, Inbred C57BL; Monocytes; Non-alcoholic Fatty Liver Disease; Obesity; Protein Kinase Inhibitors; Signal Transduction; Sterol Regulatory Element Binding Proteins; Tumor Necrosis Factor-alpha

2018
Critical Roles of the Histone Methyltransferase MLL4/KMT2D in Murine Hepatic Steatosis Directed by ABL1 and PPARĪ³2.
    Cell reports, 2016, 11-01, Volume: 17, Issue:6

    Topics: Animals; Diet, High-Fat; Histone-Lysine N-Methyltransferase; Imatinib Mesylate; Liver; Mice; Mice, Mutant Strains; Mice, Obese; Non-alcoholic Fatty Liver Disease; PPAR gamma; Protein Binding; Proto-Oncogene Proteins c-abl; Response Elements; Transcriptional Activation; Transcriptome

2016